UPDATE : Monday, September 7, 2020
상단여백
HOME Pharma
Daewoong exports Botox to Brazil and Egypt
  • By Lee Han-soo
  • Published 2018.01.29 15:39
  • Updated 2018.01.29 15:39
  • comments 0

Daewoong said Monday that it has signed an agreement with Moksha8, a Brazilian pharmaceutical company, and EIMS, an Egyptian aesthetic company, to export Nabota, the company’s botulinum toxin (BTX) type A product.

The company plans to supply $16 million worth of Nabota to Moksha8 for five years, while also providing $5 million worth of Nabota to EIMS during the same period.

“Through this Nabota export contract, the company has secured a bridgehead for entering the market in Brazil and the Middle East, strengthening its position in the global market,” said Park Sung-soo, Daewoong’s Nabota business manager. “We will continue to promote overseas business opportunities by informing Nabota's superior quality in the global market based on its superior product strength.”

The news came after U.S. Food and Drug Administration (FDA) recently raised issues with the company's claims regarding Nabota's superior quality. The FDA pointed out 10 problems with Daewoong Pharmaceutical’s Nabota plant, in a due diligence report last Monday.

According to the report, the factory’s aseptic processing areas are deficient regarding the system for monitoring environmental conditions. The U.S. agency also noted that the facility needs separate or defined areas, or such control systems for the firm’s operation necessary to prevent contamination or mix-up during aseptic processing.

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top